Pemetrexed Pfizer 25 mg/ml concentrate for solution for infusion.

DRUG2 trials

Sponsors

Glaxosmithkline Research & Development Limited, F. Hoffmann-La Roche AG

Conditions

Lung CancerNon-Small CellResectable Stage I-III Non-Small Cell Lung Cancer (NSCLC)

Phase 2

A RANDOMIZED, PHASE 2, DOUBLE-BLIND STUDY TO EVALUATE THE EFFICACY OF DOSTARLIMAB PLUS CHEMOTHERAPY VERSUS PEMBROLIZUMAB PLUS CHEMOTHERAPY IN METASTATIC NON-SQUAMOUS NON-SMALL CELL LUNG CANCER

CompletedCTIS2023-505894-33-00

Glaxosmithkline Research & Development LimitedLung Cancer, Non-Small Cell

Start: 2020-11-25End: 2024-09-10Target: 114Updated: 2024-02-29

Phase 3

A Phase I-III, Multicenter Study Evaluating the Efficacy and Safety of Multiple Therapies in Cohorts of Patients with Resectable Stage I-III Non-Small Cell Lung Cancer, selected according to Biomarker Status

RecruitingCTIS2024-511239-91-00

F. Hoffmann-La Roche AGResectable Stage I-III Non-Small Cell Lung Cancer (NSCLC)

Start: 2025-05-05Target: 54Updated: 2025-11-10